Paradromics Wins FDA Approval to Let Patients Use Personal Devices With Its BCI

Summary

Paradromics received an FDA approval letter expanding which computing devices patients can use with its investigational Connexus brain-computer interface, within the ongoing Connect-One Early Feasibility Study. Previously limited to company-provided hardware, the approval lets patients connect personal laptops, tablets, and phones through Convey, the system that translates decoded neural intent into device control, without requiring separate FDA sign-off for each device type. CEO Matt Angle framed the move as a step toward a BCI that "moves with the user rather than tethering him or her to a fixed computing environment."